S113: IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

• DOI: 10.1097/01.hs9.0000967364.68535.18
• Publication Date: 2023-08-08T13:01:27Z
• Authors: Zihong Cai; Ting Zhang; Suning Chen; Liang Huang; Qifa Liu; Hongsheng Zhou
• Keywords: Immunophenotyping; CAR T-cell therapy

Background: Although CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) has emerged as one of the promising therapeutic approaches to relapsed and/or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), more than half recipients will ultimately experience disease progression. Mounting evidence shows that resistance CAR-T influenced by factors not only related effector cells, but target cells. Previous studies have shown poor outcome conferred IKZF1 deletions, been explored in context CAR therapy. Therefore, it is necessary explore impact deletion on prognostic value patients receiving Aims: We determined assess effect therapy, mechanism resistance, and develop a potential strategy for these patients. Methods: Here we enrolled two cohorts analyze deletion. The first cohort included 129 from three centers. After that, 113 was establish whether T can overcome genetic adverse features, deletion, induce remission. Results: Within cohort, inferior EFS observed group (P=0.041, Fig.A). In multivariable Cox regression model adjusting contributing event-free survival, including Ph status, immunophenotype, chromosome karyotype, remained independently associated with survival (P=0.025, Fig.B). rates were comparable no-CAR-T (Fig.C). cannot abrogate dismal models (P=0.157, Fig.D). Summary/Conclusion: potent tumor-intrinsic biomarker inform risk stratification clinical trial design B-ALL treated CD19-CAR-T. Further mechanisms are needed how tumor intrinsic phenotype promote antitumor immune response, could represent targets potentiate efficacy therapy.Keywords: CAR-T, Adult, Acute